Ngā hua rapu - Stephen Gottschalk

Whakamahine hua
  1. 1
    CAR T Cells for Solid Tumors

    CAR T Cells for Solid Tumors mā Sunitha Kakarla, Stephen Gottschalk

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Engineered Cytokine Signaling to Improve CAR T Cell Effector Function

    Engineered Cytokine Signaling to Improve CAR T Cell Effector Function mā Matthew Bell, Stephen Gottschalk

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Adoptive T-Cell Immunotherapy

    Adoptive T-Cell Immunotherapy mā Stephen Gottschalk, Cliona M. Rooney

    I whakaputaina 2015
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors

    Genetic Modification Strategies to Enhance CAR T Cell Persistence for Patients With Solid Tumors mā Christopher DeRenzo, Stephen Gottschalk

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Cancer-Associated Fibroblasts as Targets for Immunotherapy

    Cancer-Associated Fibroblasts as Targets for Immunotherapy mā Sunitha Kakarla, Xiao‐Tong Song, Stephen Gottschalk

    I whakaputaina 2012
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy

    A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy mā Rebecca Epperly, Stephen Gottschalk, Mireya Paulina Velasquez

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy

    Rewriting History: Epigenetic Reprogramming of CD8+ T Cell Differentiation to Enhance Immunotherapy mā Caitlin C. Zebley, Stephen Gottschalk, Ben Youngblood

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Redirecting T cells to hematological malignancies with bispecific antibodies

    Redirecting T cells to hematological malignancies with bispecific antibodies mā Mireya Paulina Velasquez, Challice L. Bonifant, Stephen Gottschalk

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Allogeneic CAR Cell Therapy—More Than a Pipe Dream

    Allogeneic CAR Cell Therapy—More Than a Pipe Dream mā Kenneth J. Caldwell, Stephen Gottschalk, Aimee C. Talleur

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    Design and development of therapies using chimeric antigen receptor‐expressing T cells

    Design and development of therapies using chimeric antigen receptor‐expressing T cells mā Gianpietro Dotti, Stephen Gottschalk, Barbara Savoldo, Malcolm K. Brenner

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?

    CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality? mā Jessica Wagner, Elizabeth Wickman, Christopher DeRenzo, Stephen Gottschalk

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma

    Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma mā Zhongzhen Yi, Brooke Prinzing, Felicia Cao, Stephen Gottschalk, Giedre Krenciute

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    A Vaccine That Co-Targets Tumor Cells and Cancer Associated Fibroblasts Results in Enhanced Antitumor Activity by Inducing Antigen Spreading

    A Vaccine That Co-Targets Tumor Cells and Cancer Associated Fibroblasts Results in Enhanced Antitumor Activity by Inducing Antigen Spreading mā Stephen Gottschalk, Yu Feng, Minjun Ji, Sunitha Kakarla, Xiao‐Tong Song

    I whakaputaina 2013
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    Is cancer gene therapy an empty suit?

    Is cancer gene therapy an empty suit? mā Malcolm K. Brenner, Stephen Gottschalk, Ann M. Leen, Juan F. Vera

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Sequential processing of lysosomal acid phosphatase by a cytoplasmic thiol proteinase and a lysosomal aspartyl proteinase.

    Sequential processing of lysosomal acid phosphatase by a cytoplasmic thiol proteinase and a lysosomal aspartyl proteinase. mā Stephen Gottschalk, Abdül Waheed, B Schmidt, Piotr Laidler, Kurt Von Figura

    I whakaputaina 1989
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    MyD88/CD40 signaling retains CAR T cells in a less differentiated state

    MyD88/CD40 signaling retains CAR T cells in a less differentiated state mā Brooke Prinzing, Patrick Schreiner, Matthew Bell, Yiping Fan, Giedre Krenciute, Stephen Gottschalk

    I whakaputaina 2020
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Synapse-tuned CARs enhance immune cell anti-tumor activity

    Synapse-tuned CARs enhance immune cell anti-tumor activity mā Peter Chockley, Jorge Ibañez-Vega, Giedre Krenciute, Lindsay J. Talbot, Stephen Gottschalk

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models

    Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models mā Melinda Mata, Claudia Gerken, Phuong Nguyen, Giedre Krenciute, David M. Spencer, Stephen Gottschalk

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours

    Chimeric Antigen Receptor-modified T cells targeting EphA2 for the immunotherapy of paediatric bone tumours mā Kenneth Hsu, Shiloh Middlemiss, Federica Saletta, Stephen Gottschalk, Geoffrey McCowage, Belinda Kramer

    I whakaputaina 2020
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

    Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma mā Nino Rainusso, Vita S. Brawley, Alexia Ghazi, John Hicks, Stephen Gottschalk, Jeffrey M. Rosen, Nabil Ahmed

    I whakaputaina 2011
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: